Sunmax Biotech (雙美) has officially launched its fourth-generation aesthetic injectable, "Sunmax Deusaderm ULTRA Collagen Implant with Lidocaine" (膚漾美), in Taiwan. With enhanced durability and broader application, the product is expected to drive significant momentum alongside the company’s expansion into ASEAN markets.

Operational Highlights:

• Product Matrix: The collagen-based injectable portfolio spans four generations (FacialGain, FacialFill, FacialLift, and Faceryal). Rather than replacing one another, these products form a complete matrix for varying clinical needs.
• Manufacturing and Revenue: The new plant received QMS certification in May. Mass production will commence once product certifications are finalized. While 2025 YTD revenue reached NT$1.517 billion (+13.37% YoY) and EPS hit NT$10.43, the current gross margin of 79% reflects depreciation and certification costs of the new facility.
• ASEAN Expansion: Following successful launches in Singapore, the Philippines, and Malaysia, Sunmax targets Thailand for entry in 2026.

General Manager Lin Ming-yi expects that 2025 serves as a stable foundation year, while 2026 will see accelerated growth driven by the fourth-generation product launch and the revenue contribution from the new manufacturing plant.

Resource: 雙美新品、新市場雙引擎，2026年營運拚轉強